MUB Medical Secures Funding for Pre-clinical Trials

We are thrilled to announce that MUB Medical has received financing from Innovation Norway to conduct pre-clinical trials for Sutrips. This marks the third time that Innovation Norway has supported us financially, and we are incredibly grateful for their ongoing trust and belief in our vision.
With the backing of Innovation Norway, we are now focused on preparing for Sutrips’ global market introduction. We will actively engage with key industry players to explore potential collaborations for the successful launch of Sutrips.
It’s an exhilarating time for us, and we invite you to follow us on LinkedIn for more exciting updates. Stay tuned as we share the remarkable results of our proof of concept, which we recently completed.
Thank you for your unwavering support and enthusiasm as we work towards revolutionizing wound care with Sutrips! A simple Scandinavian solution for a complex global problem.


Introducing Sutrips

Introducing Sutrips-
Wound Closure with Adjustable Tension

We are thrilled to unveil the much-anticipated product introduction video for Sutrips, our game-changing suture tool that is set to transform the field of wound closure.


Sutrips: Precision in Every Stitch

Sutrips is not just another ordinary suture tool. It’s a breakthrough innovation that empowers healthcare professionals to achieve exceptional wound closure results. With Sutrips, we have harnessed the power of adjustable tension, allowing for a new level of precision and control in each stitch.


Advanced Technology, Optimal Healing

By providing the ability to apply different tension to each stitch, Sutrips offers unparalleled versatility and customization. This means healthcare professionals can adapt the tension to suit the specific needs of each wound, ensuring optimal healing outcomes. Whether it’s a deep laceration, a delicate incision, or any other wound type, Sutrips enables precise tension application for superior results.


Innovation at Its Finest

Sutrips represents a significant leap forward in wound closure technology. It eliminates the limitations of traditional suture tools by integrating adjustable tension capabilities into a user-friendly, all-in-one device. This not only streamlines the suturing process but also enhances patient comfort and minimizes complications.


Empowering Healthcare Professionals, Elevating Patient Care

We are proud to equip healthcare professionals with the tools they need to deliver the highest standard of care. Sutrips empowers them to achieve remarkable results, reduce procedural time, and optimize the healing journey for their patients. By harnessing the power of adjustable tension, Sutrips paves the way for advancements in wound closure techniques and improved patient outcomes.


Join Us on the Journey

We invite you to watch our product introduction video to witness the groundbreaking capabilities of Sutrips. Together, let’s revolutionize wound closure and make a lasting impact on the healthcare industry. Like, comment, and share this post to spread the word and join us on this exciting journey!


Patent Issued in Indonesia

Securing Patent in Indonesia

We are thrilled to announce that MUB Medical Solutions has successfully secured a patent for our innovative wound closure solution, Sutrips, in Indonesia. With a population of over 270 million, Indonesia represents a significant and promising market for our product.


The patent grant in Indonesia further strengthens our position and allows us, along with our esteemed partners, to enforce protection rights for the sales and distribution of Sutrips in this important market. This milestone achievement underscores our commitment to delivering cutting-edge solutions and protecting our intellectual property.


“We are delighted to receive the patent for Sutrips in Indonesia,” said Ubbat Ocak, Founder of MUB Medical Solutions. “This achievement solidifies our market presence in the region and enables us to bring our innovative wound closure technology to healthcare professionals and patients in Indonesia.”


The Indonesian market holds immense potential due to its large population and growing healthcare needs. The patent provides us with a strong foundation to establish partnerships, expand market reach, and cater to the demands of healthcare providers seeking advanced wound closure solutions.


“We recognize the significance of the Indonesian market and the opportunities it presents,” stated Yasar Shaikh, CEO of MUB Medical Solutions. “Securing the patent for Sutrips in Indonesia empowers us to deliver superior quality products while upholding our commitment to intellectual property rights and ensuring the best outcomes for healthcare professionals and patients alike.”


MUB Medical Solutions remains dedicated to innovation, research, and development to continuously improve the wound closure process. The patent grant in Indonesia is a testament to our relentless pursuit of excellence and our determination to provide state-of-the-art solutions to healthcare providers globally.


As we continue to expand our market presence in Indonesia and other strategic regions, we invite healthcare professionals, distributors, and potential partners to join us on this exciting journey. Together, we can make a significant impact on the wound closure industry and enhance patient care.


Stay connected with MUB Medical Solutions through our website and social media channels for the latest updates on our products, partnerships, and advancements in the field of wound closure.


MUB Medical Joins Aleap

MUB Medical Joins Aleap in Oslo to Accelerate Commercialization

We are thrilled to announce that MUB Medical Solutions has joined Aleap, the largest incubator for health startups in the Nordics. This exciting partnership marks a significant milestone in our journey to revolutionize wound closure with our innovative product, Sutrips.


Aleap’s unique incubator model is designed to support ambitious entrepreneurs in building successful growth companies. With access to world-class competence, a vast network of industry experts, and funding opportunities, we are confident that our membership with Aleap will propel us forward on our mission.


Ubbat Ocak and Yasar Shaikh, CEOs of MUB Medical, express their enthusiasm about this collaboration. They firmly believe that joining Aleap will provide them with invaluable knowledge and connections that will expedite the process of bringing Sutrips to the market.


By becoming a part of Aleap, we are aligning ourselves with a vibrant ecosystem of like-minded innovators and industry leaders. This collaboration will undoubtedly foster an environment of collaboration, learning, and growth, enabling us to make a tangible impact in the field of wound closure.


We extend our heartfelt gratitude to Aleap for their belief in our vision and for providing us with this remarkable opportunity. We are excited to embark on this journey together and look forward to leveraging the resources and support offered by Aleap to bring Sutrips to healthcare providers and patients worldwide.


Stay tuned for more updates on our progress as we continue to push the boundaries of innovation and transform the landscape of wound closure.


Visiting Center For Surgical Science

MUB Medical Visits Center for Surgical Science at Zealand University Hospital

Last week, the team at MUB Medical had the privilege of visiting the prestigious Center for Surgical Science at Zealand University Hospital in Denmark. The visit proved to be an enlightening experience, as we engaged in fruitful discussions about our patented suturing technology and its potential to revolutionize the suturing process.


During our conversation, we received valuable feedback on our flagship product, Sutrips, which has the potential to significantly enhance the efficiency of suturing procedures. However, the benefits of our technology didn’t stop there. We were thrilled to discover that it holds promise for various other types of operations as well.


Building upon this positive interaction, we are excited to announce that we will be initiating collaborative work with the Center for Surgical Science to explore the development of a potential spin-off product based on our core patent. This collaboration opens up new avenues for innovation and reinforces our commitment to advancing medical technologies.


At MUB Medical, we understand the importance of engaging with end-users and gathering industry insights. It is through these interactions that we can refine our products to better meet the needs of healthcare professionals and patients alike. We are grateful for the opportunity to collaborate with esteemed institutions like the Center for Surgical Science and look forward to the possibilities that lie ahead.


Stay tuned for more updates as we continue our journey of transforming the field of wound closure and improving healthcare outcomes.


Patent Issued in Australia

MUB Medical Secures Patent Approval for Sutrips in Australia

MUB Medical Solutions, a leading innovator in the field of wound closure, is thrilled to announce the approval and issuance of a patent for their groundbreaking product, Sutrips, in Australia.


The approval of the patent marks a significant milestone for MUB Medical, validating the uniqueness and inventive attributes of Sutrips. This achievement reinforces the company’s commitment to revolutionizing the field of wound closure and making a lasting impact on patient care worldwide.


Australia, with its thriving healthcare sector and commitment to innovation, is a strategic market for MUB Medical. The patent approval strengthens the company’s intellectual property rights and positions them for growth and market expansion in the region.


Sutrips, a state-of-the-art solution developed by MUB Medical, empowers healthcare professionals to efficiently and effectively close wounds. By enabling on-site wound closure, Sutrips eliminates the need for immediate patient transportation to medical facilities, resulting in improved outcomes and cost savings for healthcare providers.


“We are delighted to receive patent approval for Sutrips in Australia,” said Ubbat Ocak, Founder and Chief Technology Officer of MUB Medical Solutions. “This significant milestone reflects our dedication to innovation and our mission to enhance wound closure practices globally. We are excited to bring Sutrips to healthcare professionals in Australia, enabling them to deliver optimal care to patients.”


MUB Medical Solutions remains committed to protecting their intellectual property and ensuring that Sutrips continues to deliver groundbreaking solutions to the wound closure industry. The company’s ongoing efforts to secure patents in key strategic markets demonstrate their dedication to providing the best possible IP protection for their partners and customers.


With the Australian patent approval, MUB Medical is poised to expand its presence in the region, bringing the benefits of Sutrips to healthcare professionals and patients across the country.


Patent approved in South Africa

MUB Medical Secures Patent in South Africa, Advancing Accessible Wound Closure in Africa

MUB Medical Solutions, a leading innovator in the field of healthcare, is delighted to announce the successful granting of a patent for their revolutionary wound closure device, Sutrips, in South Africa. This patent approval marks a significant step forward in MUB Medical’s mission to improve access to effective wound closure solutions across the African continent.


South Africa, with its vast rural areas and limited access to medical facilities, faces unique challenges when it comes to wound care. Time, distance, and the cost of treatments are major considerations for both healthcare providers and patients. Recognizing this pressing need, MUB Medical developed Sutrips, which stands as one of the simplest and most efficient wound closure devices globally.


Sutrips empowers healthcare workers, including non-specialists, to confidently and securely close wounds on-location, eliminating the need for transportation to distant medical facilities. This breakthrough technology not only saves precious time but also reduces the financial burden associated with traditional wound closure methods.


By securing the patent in South Africa, MUB Medical paves the way for wider adoption of Sutrips throughout the African continent. The company remains committed to transforming wound closure by making it accessible and affordable to everyone, regardless of their geographical location.


The granting of the patent in South Africa reinforces MUB Medical’s dedication to improving healthcare outcomes and addressing the specific needs of communities in rural areas. This achievement sets the stage for expanding partnerships, collaborating with healthcare providers, and delivering high-quality wound closure solutions that positively impact patient care.


MUB Medical is excited to continue its journey of innovation and looks forward to working closely with healthcare professionals, stakeholders, and partners across Africa to revolutionize wound closure and improve the lives of patients everywhere.


Patent Issued in Euroasia

MUB Medical Secures Patent Approval in the Euroasia Region, Unlocking New Business

The approval of the patent in Euroasian countries marks a major achievement for MUB Medical. It validates the unique and innovative nature of their product and establishes a strong legal foundation for protecting their intellectual property in these countries. With the Euroasia region being a prominent market in the medical sector, this patent approval opens up exciting prospects for MUB Medical to expand their presence and drive growth.


By securing the patent in the Euroasia region, MUB Medical gains a competitive edge and enhanced market positioning. It enables them to explore new partnerships, collaborations, and licensing opportunities within this dynamic and rapidly evolving region. The patent approval not only solidifies MUB Medical’s commitment to innovation but also reinforces their dedication to providing cutting-edge solutions to healthcare professionals and improving patient outcomes.


“We are delighted to receive patent approval in the Euroasia region,” said Ubbat Ocak, Founder of MUB Medical. “This is a testament to the hard work and expertise of our team. It opens up exciting possibilities for us to expand our presence in this strategically developing region and collaborate with key stakeholders to make a positive impact on healthcare.”


With the patent now in place, MUB Medical is well-positioned to capitalize on the growing demand for their innovative solutions in the Euroasia region. They are excited about the future possibilities and are committed to delivering excellence in medical technology while driving positive change in healthcare systems across the Euroasia region.


Innovation Norway Grant Funding

MUB Medical Secures Funding from Innovation Norway to Advance Innovation and Development Efforts

MUB Medical Solutions, a leading medical technology company, is excited to announce that it has been granted funding from Innovation Norway, a government agency supporting innovation and development in various industries. This funding will play a crucial role in propelling MUB Medical’s ongoing work towards prototyping, developing mass production methodologies, and assessing the feasibility of its groundbreaking medical solutions.


The funding received from Innovation Norway serves as a validation of MUB Medical’s innovative approach and underscores the agency’s confidence in the company’s potential to drive advancements in the medical technology sector. With this financial support, MUB Medical will be able to further accelerate its research and development initiatives, bringing them closer to the realization of their transformative medical solutions.


MUB Medical’s focus on prototyping and developing mass production methodologies will enable the company to enhance the scalability and efficiency of its products, making them accessible to a broader audience. By leveraging the funding from Innovation Norway, MUB Medical aims to streamline its manufacturing processes, optimize cost-efficiency, and ensure the highest quality standards for its medical solutions.


Moreover, the feasibility assessment made possible by this funding will provide valuable insights into the practicality and potential impact of MUB Medical’s innovative concepts. This crucial step will help guide the company’s future endeavors, ensuring that their solutions align with market needs and regulatory requirements.


Securing funding from Innovation Norway represents a significant milestone for MUB Medical. It not only provides the financial support necessary for continued progress but also acknowledges the company’s dedication to driving innovation in the medical technology field. The funding reinforces MUB Medical’s commitment to transforming healthcare practices and improving patient outcomes through cutting-edge solutions.


MUB Medical is grateful for the opportunity to collaborate with Innovation Norway and leverage their expertise and resources. This partnership will enable the company to leverage a broad range of support services, networks, and guidance, ultimately accelerating the development and commercialization of their groundbreaking medical solutions.


As MUB Medical moves forward with its prototyping, mass production development, and feasibility assessment, the company remains committed to collaboration, research, and a patient-centered approach. They continue to seek out opportunities for partnerships and industry collaborations to further advance their mission of revolutionizing healthcare through innovative technology.


Patent Granted in Norway

MUB Medical Secures National Patent for Sutrips in Norway, Advancing Global Patenting Strategy

MUB Medical Solutions, a leading medical technology company based in Skien, Norway, is thrilled to announce the successful granting of a national patent for their innovative wound closure device, Sutrips. This milestone marks the completion of the first step in MUB Medical’s comprehensive global patenting strategy for Sutrips.


The granting of the national patent in Norway validates the uniqueness and inventiveness of Sutrips, further solidifying MUB Medical’s position as a pioneer in the field of wound closure. This achievement is a testament to the dedication and expertise of the MUB Medical team, as well as their commitment to driving advancements in healthcare.


Sutrips, an all-in-one device for wound closure, has been meticulously designed with simplicity and effectiveness in mind. It empowers healthcare professionals to securely close wounds with ease, offering a user-friendly solution that enhances patient care and improves treatment outcomes.


Securing the national patent in Norway is a significant milestone for MUB Medical, enabling them to protect their intellectual property rights and pave the way for future commercialization opportunities. This achievement not only reinforces MUB Medical’s commitment to innovation but also positions them as a key player in the global wound closure market.


As part of its broader global patenting strategy, MUB Medical will continue pursuing patent registrations in strategic markets worldwide. By safeguarding their intellectual property, MUB Medical aims to ensure the long-term success and market exclusivity of Sutrips, while advancing their mission to transform wound closure practices and improve patient well-being globally.


The completion of the first step in the global patenting strategy marks an exciting phase for MUB Medical. With their base in Skien, Norway, the company is proud to contribute to the nation’s thriving innovation ecosystem and drive advancements in healthcare technology. This achievement strengthens MUB Medical’s position as a leader in the field and opens doors for further growth and collaboration opportunities.


MUB Medical remains committed to ongoing research, development, and collaboration with healthcare professionals and industry partners. They continue to explore new avenues for advancing wound closure practices and delivering innovative solutions that positively impact patients’ lives.